Specifically, the kits provide prior authorization information for PCSK9 inhibitors to treat lipid disorders, direct oral anticoagulants for stroke prevention and angiotensin receptor-neprilysin inhibitors for heart failure treatment. Those three categories of drugs were commonly pinpointed as being “always” or “often” denied by insurance companies in surveys of providers.

Last week, the Kansas Insurance Department announced the state will require all health insurers to cover 3D mammograms by 2019, according to an Aug. 9 article by the Kansas City Star.

CVS Health’s takeover of health insurance giant is likely close to clearing the antitrust process with the Department of Justice, Bloomberg reported last week.

A technologist at Mississippi Baptist Medical Center in Jackson, Mississippi, has been fired for using a racial slur Aug. 11 at a local donut shop.

National health spending rose 5.2 percent to $3.66 trillion in June 2018 from the previous year, according to a new insights report from Alarum.

Jack W. Jennings, MD, PhD, has been named the new chief of musculoskeletal radiology at the Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis.

On Aug. 9, the FDA expanded its list of valsartan products currently under recall to include other items that contain the active ingredient, which may be tainted with a carcinogenic impurity, manufactured by Hetero Labs Limited in India.

Public Health England announced late this week bowel cancer screening in the country will now start at age 50, not 60, the BBC reported.